A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Chang
University of Glasgow
Study Chair - Jeff Evans
University of Glasgow
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Hospitals Bristol Nhs Foundation Trust
Bristol, United Kingdom
- University Hospitals Coventry & Warwickshire
Coventry, United Kingdom
- Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
- Royal Free London Hospital
London, United Kingdom
- Royal Marsden Hospital
London, United Kingdom
- the Christie Hospital
Manchester, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Jun 2024
- Primary completion
- 23 May 2025
- Completion
- 23 May 2025
- Last update posted
- 11 Jul 2025
- Registered enrollment
- 0
- Registry id
- NCT06498518
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.